Q1 2027 Fredun Pharmaceuticals Ltd Earnings Call Transcript
Key Points
- Strong Q1 FY27 performance with total income up 90.44% YoY to INR228.25 crores, EBITDA up 92.90% to INR32.78 crores, and net profit up 94.63% to INR13.17 crores.
- Management guides for 30-35% blended revenue growth over the next 3-5 years, driven by new-age brands growing 35-45% and vintage business growing 15-20%.
- Expansion of manufacturing capacity with 43 new locations at Balgar and planned CapEx of INR30-40 crores annually for the next two years to support growth.
- Pet care business, including functional foods and the new VAGA.in platform, is growing 40-50% YoY, with plans to launch cat food and diagnostics, targeting INR100 crores in cat food sales within 3.5 years.
- Improving operational efficiency with inventory days down ~50% over two years, targeting 120 days, and interest costs reducing due to better cash flows and credit rating upgrade to BBB+.
- Strong management team with low attrition, experienced CEOs for each division, and a robust R&D pipeline for new product launches.
- Q1 is historically the weakest quarter due to seasonality, with growth partly boosted by one-time advance orders booked at favorable prices in the previous quarter.
- Management refrains from committing to specific revenue targets, only guiding for ~INR800 crores for FY27, which may disappoint investors expecting INR1,000 crores.
- Working capital is expected to increase in absolute terms as revenue grows, though it remains manageable at ~INR170-175 crores.
- Inventory days remain high at ~140 days, though management targets reducing to 120 days within four quarters.
- Margin expansion is expected to be gradual, with a potential spike only after 8-11 quarters, as the company prioritizes market penetration over immediate profitability.
- The pet care business is still at a small base, and the success of new initiatives like VAGA.in and cat food is yet to be proven.
Ladies and Gentlemen, good day and welcome to the Q1FY27 Results Conference Call of Fredun Pharmaceuticals Ltd.
This conference call may contain forward-looking statements about the company which are based on the beliefs, opinions and expectations of the company as on the date of this call.
These statements are not the guarantees of future performance and enrolled risks and uncertainties that are difficult to predict. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal our payout by pressing star then zero on your touchtone phone. Please note that this conference is being recorded.
I now hand the conference over to Ms. Saakshi Panjiyara.
Thank you and over to you, ma'am.
Good morning, everyone.
Thank you for joining the Q1 FY '27 earnings conference call of Fredun
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
